Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences to Host Conference Call and Webcast of Fourth Quarter and Year End 2014 Results on Monday, March 16

PR Newswire March 9, 2015

BioDelivery Sciences to Present at the 27th Annual ROTH Conference

PR Newswire March 3, 2015

BioDelivery Sciences to Receive $10 Million Milestone Payment from Endo Pharmaceuticals Inc. in Conjunction with Acceptance of NDA for BELBUCA(TM) (buprenorphine HCl) Buccal Film for Chronic Pain

PR Newswire February 23, 2015

Endo Pharmaceuticals and BioDelivery Sciences Announce Acceptance of NDA for BELBUCA(TM) (buprenorphine HCl) Buccal Film for the Management of Chronic Pain

PR Newswire February 23, 2015

BioDelivery Sciences to Present at the 2015 RBC Capital Markets Healthcare Conference

PR Newswire February 18, 2015

BioDelivery Sciences Acquires North American Marketing Authorizations for ONSOLIS from Meda

PR Newswire January 27, 2015

Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain

Canada NewsWire December 23, 2014

BioDelivery Sciences Launches InReach Support Program for Those Affected by Opioid Dependence

PR Newswire December 10, 2014

BioDelivery Sciences Announces Completion of Randomization in Phase 3 Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy

PR Newswire December 8, 2014

BioDelivery Sciences to Present at the 26th Annual Piper Jaffray Healthcare Conference

PR Newswire November 25, 2014

BioDelivery Sciences to Present at the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global Healthcare Conference

PR Newswire November 13, 2014

BioDelivery Sciences to Present at the Credit Suisse 2014 Healthcare Conference

PR Newswire November 7, 2014

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Third Quarter 2014 Financials

PR Newswire November 5, 2014

BioDelivery Sciences Announces the Availability of BUNAVAIL(TM) in the U.S.

PR Newswire November 3, 2014

BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain

PR Newswire October 28, 2014

BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance

PR Newswire October 10, 2014

BioDelivery Sciences to Provide BUNAVAIL Launch Update

PR Newswire October 6, 2014

US Patent Office Institutes Inter Partes Review Brought by MonoSol Rx Against All Claims in Key BDSI BEMA Patent

GlobeNewswire October 6, 2014

BioDelivery Sciences to Present at the Morgan Stanley Global Healthcare Conference

PR Newswire September 8, 2014

BioDelivery Sciences International Inc. (BDSI) Jumps 8.94% on September 5

Equities.com September 5, 2014